AVEO Pharmaceuticals Stock Forecast, Price & News

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

Is AVEO Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVEO Pharmaceuticals stock.
View analyst ratings for AVEO Pharmaceuticals or view top-rated stocks.

How has AVEO Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVEO shares have increased by 56.4% and is now trading at $5.46.
View which stocks have been most impacted by COVID-19.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for AVEO Pharmaceuticals.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.06. The biopharmaceutical company earned $15.17 million during the quarter, compared to analyst estimates of $14.29 million. AVEO Pharmaceuticals had a negative net margin of 225.54% and a negative trailing twelve-month return on equity of 105.47%. During the same quarter last year, the company earned ($0.33) earnings per share.
View AVEO Pharmaceuticals' earnings history.

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

AVEO Pharmaceuticals's stock reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

2 equities research analysts have issued 1-year price objectives for AVEO Pharmaceuticals' stock. Their forecasts range from $18.00 to $19.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 238.8% from the stock's current price.
View analysts' price targets for AVEO Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:

• Michael P. Bailey, President, Chief Executive Officer & Director (LinkedIn Profile)
• Erick J. Lucera, Chief Financial Officer
• Michael N. Needle, Chief Medical Officer
• Matthew Coulter, Vice President-Information Technology
• Stefanie Solomon, Head-Compliance

What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?

4 employees have rated AVEO Pharmaceuticals CEO Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among AVEO Pharmaceuticals' employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AVEO Pharmaceuticals' key competitors?

Some companies that are related to AVEO Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of AVEO's competitors.

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (5.78%), Millennium Management LLC (2.04%), BlackRock Inc. (1.55%), Opaleye Management Inc. (1.33%), Goldman Sachs Group Inc. (0.82%) and Geode Capital Management LLC (0.73%). Company insiders that own AVEO Pharmaceuticals stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends for AVEO Pharmaceuticals.

Which major investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Citadel Advisors LLC, Dimensional Fund Advisors LP, and Jane Street Group LLC.
View insider buying and selling activity for AVEO Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying AVEO Pharmaceuticals stock?

AVEO stock was acquired by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Millennium Management LLC, Brandywine Global Investment Management LLC, BlackRock Inc., Pura Vida Investments LLC, GSA Capital Partners LLP, Cubist Systematic Strategies LLC, and Grimes & Company Inc.. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Michael Ferraresso, Michael P Bailey, and Peter W Sonsini.
View insider buying and selling activity for AVEO Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $5.46.

How much money does AVEO Pharmaceuticals make?

AVEO Pharmaceuticals has a market capitalization of $187.68 million and generates $6.02 million in revenue each year. The biopharmaceutical company earns $-35.58 million in net income (profit) each year or ($1.95) on an earnings per share basis.

How many employees does AVEO Pharmaceuticals have?

AVEO Pharmaceuticals employs 94 workers across the globe.

When was AVEO Pharmaceuticals founded?

AVEO Pharmaceuticals was founded in 2001.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is www.aveooncology.com.

Where are AVEO Pharmaceuticals' headquarters?

AVEO Pharmaceuticals is headquartered at 30 WINTER STREET, BOSTON MA, 02108.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at (617) 400-0101, via email at [email protected], or via fax at 617-995-4995.